An Open-label, Multicentre, Extension Trial to Assess the Safety of Re-dosing of Intravenous Iron Isomaltoside (Monofer)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Iron isomaltoside 1000 (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- Acronyms FerWonExt
- Sponsors Pharmacosmos
- 14 Mar 2018 Planned End Date changed from 1 Oct 2020 to 1 Nov 2018.
- 14 Mar 2018 Planned primary completion date changed from 1 May 2020 to 1 Nov 2018.
- 14 Mar 2018 Status changed from recruiting to active, no longer recruiting.